Drugs / IMA101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02876510 | Jun 2017 → Sep 2021 | cancer | Immatics US, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-11-10 | Immatics Biotechnologies GmbH | Results Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference immatics.com ↗
Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence. |
| 2019-07-19 | Immatics Biotechnologies GmbH | Results Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients immatics.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-11-10 | Immatics Biotechnologies GmbH | Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference immatics.com ↗ |
| 2019-07-19 | Immatics Biotechnologies GmbH | Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients immatics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876510 ↗ |
| Route | Intravenous | “i.v. infusion of IMA101 product(s).” NCT02876510 ↗ |